biotechs

24 cell therapy & stem cell stocks I’m following

stem cell stocks

Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell therapy arena. Today …

24 cell therapy & stem cell stocks I’m following Read More »

Bluebird bio sickle cell gene therapy trial halted on cancer worry

bluebird bio, sickle cell gene therapy

Recently I was going through a list I’m updating of regenerative medicine biotech companies including Bluebird bio. Now just a few days later the world seems turned upside down for the firm and maybe to some degree for other companies doing related work. Bluebird bio blues: 2 trial participants get cancer News broke today that …

Bluebird bio sickle cell gene therapy trial halted on cancer worry Read More »

Recommended reads: COVID-19 updates, FDA stem cell nod, PRC2, more

Fig.-3d-Rai-et-al-Nature-Communications-2020

Today’s post is the latest edition of my weekly recommended reads, which this week include Fate Therapeutics, COVID-19 updates, AAMC, and more including some great pubs such as one on 2 modes of PRC2 function. Also check out this handy resource: Helpful 2020 List of Stem Cell Journals and this blast from the past post of 10 …

Recommended reads: COVID-19 updates, FDA stem cell nod, PRC2, more Read More »

New Mesoblast “COVID kid” stem cell study

Dr-Fred-Grossman-CMO-Mesoblast.

The biotech Mesoblast is starting an expanded access study of its stem cell product for kids with a severe offshoot of COVID-19. The cellular drug in this case is remestemcel-L (more below). While most children fare better than adults in dealing with COVID-19, the rare subset of kids with COVID-19 for this study have more severe …

New Mesoblast “COVID kid” stem cell study Read More »

Just one word placentas: Can Celularity live up to hype?

Celularity-e1519061558939

I’ve been blogging about stem cells now for about 8 years and the recent level of hype about and fluffy media coverage of Celularity, the biotech spun out of Celgene, ranks right up here with the most extreme past cases I’ve seen. What is Celularity and who is its leadership? It’s a new biotech focused …

Just one word placentas: Can Celularity live up to hype? Read More »

Stem cells for the flu? Pondering PR email, frailty data from Longeveron

Tompkins-Figure-2A

Stem cells for flu? For me, that idea is new. Some months back there was buzz about the stem cell biotech Longeveron related to its report on early trial data on testing infusions of mesenchymal stem cells for frailty in the aged. Frailty that pops up in some aging folks can manifest in a variety …

Stem cells for the flu? Pondering PR email, frailty data from Longeveron Read More »

ViaCyte Interview on Diabetes Stem Cell Trials & Cool Role of Gore-Tex Tech

ViaCyte

When I think of the promise of stem cells for diabetes, the privately held California stem cell firm ViaCyte is the first biotech that comes to mind now. It has promising stem cell clinical trial work building. Today’s post is a new interview with the company’s CEO Paul Laikind. For past posts on ViaCyte see here, which …

ViaCyte Interview on Diabetes Stem Cell Trials & Cool Role of Gore-Tex Tech Read More »

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte

VC-01-post-implant-final1-e1503703572933

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a …

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »

Blunt comment from stem cell industry insider in defense of RTT & Texas Law

Texit-stem-cells-e1493612428995

My recent post on the push for National Right-To-Try (RTT) including a detailed comment from ISSCR stirred some animated feedback. In the spirit of encouraging diverse discussion, here I am posting a striking comment I received from a stem cell industry insider regarding that post on RTT as it relates to stem cells and s/he was especially …

Blunt comment from stem cell industry insider in defense of RTT & Texas Law Read More »

Reading the tea leaves as new FDA commish Gottlieb blogs on regenerative medicine

Dr.-Scott-Gottlieb

New FDA Commissioner Dr. Scott Gottlieb, M.D., has in the past touched on stem cells and regenerative medicine therapies in speeches or written comments prior to starting his tenure at the agency. Now that he is Commissioner, he is poised to have direct impact on our field rather quickly and potentially with major changes in …

Reading the tea leaves as new FDA commish Gottlieb blogs on regenerative medicine Read More »